NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · LARGE CAP
Adma Biologics, Inc. ADMA
15 fiscal years on record · USD · FY2025 reported · SEC filings only
Growth
USD 510.2M
Revenue, FY2025 · full 15-year series below
Revenue $M
Net income $M
FY2025 · Revenue 510.2 · Net income 146.9
Compound annual growth
Revenue compounded at +64.6% a year over five years.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
29 cents
of every revenue dollar became profit
Operating margin
Net margin
FY2025 · Operating 37.5% · Net 28.8%
ROE
FY2025 · ROE 35.6%
Each USD of equity produced 36 cents of profit this year.
The 15-year record
15 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.5 | 0.4 | 0.3 | 0.2 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Operating income $B | 0.2 | 0.1 | 0.0 | −0.0 | −0.1 | −0.1 | −0.0 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| EBITDA $B | 0.2 | 0.1 | 0.0 | −0.0 | −0.1 | −0.1 | −0.0 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | · | · |
| Income tax $B | 0.0 | −0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | −0.0 | 0.0 | −0.0 | · |
| Net income $B | 0.1 | 0.2 | −0.0 | −0.1 | −0.1 | −0.1 | −0.0 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| Free cash flow $B | 0.0 | 0.1 | 0.0 | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| EPS, diluted $ | 0.60 | 0.81 | −0.13 | −0.33 | −0.51 | −0.88 | −0.89 | −1.45 | −1.91 | −1.61 | −1.73 | −1.81 | −2.38 | −1.39 | −16.72 |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| ROE % | 35.6 | 81.6 | −19.7 | −45.0 | −62.5 | −132.4 | −210.1 | −218.8 | −243.9 | · | −526.2 | −121.9 | −100.2 | −148.9 | −1530.1 |
| Shares out B | 0.24 | 0.24 | 0.23 | 0.22 | 0.20 | 0.10 | 0.06 | 0.00 | 0.01 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 74 reconciliationsAUDITED
Reconciled in 15 of 19 fiscal years. 20 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityBiological Products, (No Diagnostic Substances)
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2011